Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0600139 (
Prostate Cancer
)
4,540
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Clinically benign, whole untrimmed prostates were obtained from 104 patients at autopsy, completely sectioned, and examined microscopically. The histological and gross findings of the prostate were correlated with premortem prostatic acid phosphatase levels (PAP, enzymatic method, ACA, Dupont Co.) to determine how often
carcinoma of the prostate
(
CAP
) affected PAP levels and to identify other findings within the
prostate associated
with elevated PAP levels. Sixty (58%) prostates did not have
CAP
, 34 (33%) had
CAP
smaller than 1 ml in volume, and 10 (10%) had
CAP
larger than 1 ml in volume. PAP levels were elevated (greater than 1 U/L) in 8 of 60 (13%) prostates without
CAP
, in 2 of the 34 (6%) prostates with
CAP
smaller than 1 ml, and in 1 of the 10 (10%) prostates with
CAP
larger than 1 ml. These differences were not statistically significant. Likewise, a statistically significant correlation between PAP levels and patient age, patient race, severe inflammation, of high grade prostatic intraepithelial neoplasia (PIN) was not found. However, there was a statistically significant correlation between PAP levels and prostate weight (p < 0.0001). This study suggest that PAP cannot distinguish between patients with clinically undetected
CAP
and patients without
CAP
. Furthermore, elevated PAP levels are often not due to metastatic
CAP
and additional evidence should be present, even in patients with known
CAP
, before an elevated PAP level is considered to be conclusive evidence of metastatic
CAP
.
...
PMID:Prostatic acid phosphatase levels (enzymatic method) from completely sectioned, clinically benign, whole prostates. 861 55